Chief of Urologic Surgery at Beth Israel Deaconess Medical Center
Massachusetts General Hospital
I am honored to serve as the Chair of Research Council for the American Urological Association. As a physician scientist at Massachusetts General Hospital & Harvard Medical School, my clinical activities are focused on urologic oncology and surgical management of kidney, bladder and prostate cancer. My administrative responsibilities include serving as the Urology Residency Program Director and Director of Research for Department of Urology. Previously, I served as the director of the Combined Harvard Urologic Oncology Fellowship Program, an alliance between Massachusetts General Hospital and Brigham and Women’s Hospital.
My NIH funded laboratory is focused on providing personalized care for prostatic diseases. We have learned that the 5-alpha reductase 2 (5-AR2), a gene that is responsible for normal prostatic development and growth, and a target of the commonly used 5-AR inhibitors (finasteride or dutasteride), is not expressed in 30% of adult men. We have found that in the absence of 5AR-2, there is an androgenic to estrogenic switch in the prostate, raising possibilities for new alternative therapies for prostatic diseases.
As Chair of the Research Council, my goal is to enhance the research activities for the urologic community and increase the educated workforce of urologic researchers who can effectively study urologic diseases with the ultimate goal of reducing the disease burden for our patients. Through advocacy, education and promotion of grant funding mechanisms for new and established investigators, the AUA is hard at work for its constituents, and I am privileged to be part of that mission.